Isracann Biosciences Inc. (IPOT.CN)
| Previous Close | 0.0400 |
| Open | 0.0450 |
| Bid | 0.0450 x N/A |
| Ask | 0.0500 x N/A |
| Day's Range | 0.0400 - 0.0450 |
| 52 Week Range | 0.0350 - 0.1700 |
| Volume | |
| Avg. Volume | 63,423 |
| Market Cap | 7.123M |
| Beta (5Y Monthly) | -0.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1630 |
| Earnings Date | Apr 27, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Isracann Biosciences Announces Closing of First Tranche of $0.05 Unit Private Placement
VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement. The Company issued 4,679,600 units (the “Units”) at a price of $0.05 per Unit for aggregate gross proceeds of $233,980 (the “Offering”). Each Unit consists of one common share of the Company (a “Share”) and one common share purchase wa
- GlobeNewswire
Isracann Biosciences Subsidiary Praesidio Health Submits NPNs to Health Canada
VANCOUVER, British Columbia, May 19, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division in Canada and holdings in Israel, is pleased to announce that its wholly owned subsidiary Praesidio Health has completed the natural product number (NPN) submissions to Health Canada for its first formulations. Praesidio Health (https://www.praesidiohealth.com/) is a Canadian medical re
- GlobeNewswire
Isracann Biosciences Renews Leadership to Meet Changing Demands
VANCOUVER, British Columbia, April 15, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that further to its acquisition of Praesidio Health Inc. as a natural health medicine division, the Company has elected to expand its leadership team effective immediately. As Isracann moves from development to operations, and to better accommodate the integration of natural health medicine (“NHM”) research and development to mee
